| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA597: Dapagliflozin with insulin for treating type 1 diabetes |
|
Medicine details |
|
| Medicine name | dapagliflozin (Forxiga®) |
| Formulation | 5 mg and 10 mg film-coated tablet |
| Reference number | 4128 |
| Indication | Treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/04/2019 |
| NICE guidance | TA597: Dapagliflozin with insulin for treating type 1 diabetes |